Approval of the First Nonprescription Oral Contraceptive Pill.


Journal

Journal of obstetric, gynecologic, and neonatal nursing : JOGNN
ISSN: 1552-6909
Titre abrégé: J Obstet Gynecol Neonatal Nurs
Pays: United States
ID NLM: 8503123

Informations de publication

Date de publication:
14 Aug 2024
Historique:
medline: 18 8 2024
pubmed: 18 8 2024
entrez: 17 8 2024
Statut: aheadofprint

Résumé

In July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel 0.075 mg), a progestin-only tablet to prevent pregnancy to be used without a prescription. Although progestin-only birth control pills were approved in 1973, it has taken 50 years for the first oral contraceptive pills to be sold over the counter. In this column, I review the evidence on the barriers to access oral contraceptive pills, the efficacy, preferences and support of a nonprescription progestin-only pill, the cost, and policy implications for health insurance coverage. I conclude with recommendations from professional organizations on over-the-counter access to hormonal contraception.

Identifiants

pubmed: 39153740
pii: S0884-2175(24)00261-2
doi: 10.1016/j.jogn.2024.08.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Classifications MeSH